Sanuwave Health (SNWV) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Voting matters and shareholder proposals
Election of five directors: Morgan Frank, Gregory Bazar, Jeffrey Blizard, Ian Miller, and James Tyler, with board recommending a vote for all nominees.
Ratification of Baker Tilly US, LLP as independent registered public accounting firm for fiscal year ending December 31, 2026, recommended for approval.
Advisory, non-binding vote to approve compensation paid to named executive officers, recommended for approval.
Additional business may be addressed if properly brought before the meeting or any adjournment.
Board of directors and corporate governance
Board slate includes five nominees for election at the annual meeting.
Executive compensation and say-on-pay
Shareholders to cast an advisory, non-binding vote on executive officer compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Sanuwave Health
- Q1 2025 revenue rose 61% to $9.3M with record placements, margin gains, and ongoing risk factors.SNWV
Q1 20259 Jul 2026 - Merger deadline extended to June 30, targeting Cboe listing and 50% revenue growth.SNWV
M&A Announcement8 Jul 2026 - Record Q2 revenue and net income, with strong Q3 growth expected but ongoing capital risks.SNWV
Q2 20241 Jul 2026 - UltraMIST leverages clinical evidence and a consumables model to drive growth amid industry shifts.SNWV
Planet MicroCap Las Vegas 202618 Jun 2026 - Innovative ultrasound wound care system drives growth with high margins and strong clinical results.SNWV
Investor presentation17 Jun 2026 - Director elections, auditor ratification, and executive pay were voted on; results pending.SNWV
AGM 202611 Jun 2026 - Q1 2026 set a revenue record with improved net loss and strong outlook for continued growth.SNWV
Q1 202613 May 2026 - Annual meeting to vote on directors, auditor, and executive pay, with strong governance focus.SNWV
Proxy filing29 Apr 2026 - Record 2025 revenue and profit, with strong UltraMIST sales and robust 2026 growth outlook.SNWV
Q4 202527 Mar 2026